Nasopharyngeal carcinoma
Conditions
Interventions
Experimental group:Intravenous reinfusion, local injection of TAC-T cells
Sponsors
Jinshazhou Hospital, Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years, there is no gender limit; 2. ECOG score 0-3; 3. Nectin4/NKG2DL and FAP positive (immunohistochemistry or flow cytometry); 4. Complete remission has not been achieved after the second-line treatment; disease progression occurs during any treatment, or the disease stable time is equal to or less than 6 months; or disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation; 5. There is at least one measurable lesion, and any long diameter of the lesion is required to be greater than 0.5cm, and the lesion on the PET-CT scan is ingested; 6. The absolute value of peripheral blood neutrophils >= 1000/µl, platelets >= 45,000/µl; 7. Heart, liver and kidney function: creatinine = 50%; 8. Have sufficient understanding ability and voluntarily sign the informed consent form; 9. Reproductive patients must be willing to use contraceptive methods.
Exclusion criteria
Exclusion criteria: 1. Have autologous hematopoietic stem cell transplantation within 6 weeks; 2. Received cytotoxic drugs, glucocorticoids and other targeted drugs within 2 weeks before cell collection; 3. Active autoimmune diseases; 4. Active infection that cannot be controlled; 5. HIV infection, uncontrolled HBV, HCV, and syphilis infection; 6. Known central nervous system tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events;Complete remission rate;Partial remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactLuo Rongcheng
Jinshazhou Hospital, Guangzhou University of Chinese Medicine
Outcome results
None listed